

December 5, 2016

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,


**Sub: Updates - Alembic Pharmaceuticals Limited receives ANDA
Approval for Zolmitriptan Orally Disintegrating Tablets**

This is to inform the exchange that the Company has received approval for its abbreviated new drug application (ANDA) for Zolmitriptan Orally Disintegrating Tablets for various dosages from the U.S. Food & Drug Administration (FDA). Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director – Finance & CFO

Encl: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123

PRESS RELEASE

05th December, 2016, Vadodara, India

Alembic Pharmaceuticals receives USFDA Approval for Zolmitriptan Orally Disintegrating Tablets

Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Zolmitriptan Orally Disintegrating Tablets, 2.5 mg and 5 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Zomig-ZMT® Orally Disintegrating Tablets, 2.5 mg and 5 mg, of AstraZeneca Pharmaceutical Company. Zolmitriptan orally disintegrating tablets are indicated for the acute treatment of migraine with or without aura in adults.

Zolmitriptan orally disintegrating tablets had an estimated market size of US\$ 14 million for twelve months ending December 2015 according to IMS.

Alembic now has a total of 51 ANDA approvals (45 Final approvals and 6 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembic-india.com; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE:APLLTD) (BSE:533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 - 306 11681	Phone: +91 265 - 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. INDIA • TEL : +91-0265-2280550 • FAX : +91-0265-2282837
Website : www.alembic-india.com • E-mail : alembic@alembic.co.in

CIN: L24230GJ2010PLC061123